RXi Pharmaceuticals Corp. (RXII)

0.45
0.03 6.79
NASDAQ : Health Technology
Prev Close 0.42
Open 0.43
Day Low/High 0.42 / 0.46
52 Wk Low/High 0.27 / 6.76
Volume 3.12M
Avg Volume 1.26M
Exchange NASDAQ
Shares Outstanding 18.16M
Market Cap 6.00M
EPS -5.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding For Continued Development Of Sd-rxRNA Drug Candidate For The Treatment Of Spinal Cord Injury

BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding For Continued Development Of Sd-rxRNA Drug Candidate For The Treatment Of Spinal Cord Injury

BioAxone BioSciences, Inc. announced today that, as part of a collaborative effort with RXi Pharmaceuticals Corporation (NASDAQ: RXII), it is the recipient of a grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of...

Focused on Speculative Trading: RXII, BB, CASA

Focused on Speculative Trading: RXII, BB, CASA

We have this drifting action and uncorrelated action between stocks and the indices.

Market Players Continue to Look for Reasons to Buy Rather Than to Sell

Market Players Continue to Look for Reasons to Buy Rather Than to Sell

My biggest concern about the market continues to be a paucity of perky picks.

3 Stocks Under $10 to Trade for Breakouts

3 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

Insider Trading Alert - RXII, MA And SWN Traded By Insiders

Insider Trading Alert - RXII, MA And SWN Traded By Insiders

Stocks with insider trader activity include RXII, MA and SWN

RXi Pharmaceuticals (RXII) Is Strong On High Volume Today

RXi Pharmaceuticals (RXII) Is Strong On High Volume Today

Trade-Ideas LLC identified RXi Pharmaceuticals (RXII) as a strong on high relative volume candidate

The Trend Is Up

If you turn bearish now, you'll quickly find yourself in trouble.

Ratings Changes Today

Upgrades: CEB, DAC, FARM, GIG, JOEZ, LGND, QDEL, RGC, RLOC, VCO, WSH Downgrades: AWRE, BNNY, CALX, ETR, GTS, HUN, ICE, NTT, PLOW, RDY Initiations: RXII Read on to get TheStreet Quant Ratings' detailed report:

RXi Pharmaceuticals To Present At The 25th Annual ROTH Conference

RXi Pharmaceuticals To Present At The 25th Annual ROTH Conference

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Announces $16.4 Million Placement Of Common Stock

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, and...

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals And OPKO Health Announce Strategic Pooling Of RNAi Assets

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, and...

RXi Pharmaceuticals Announces Upcoming Presentations

RXi Pharmaceuticals Announces Upcoming Presentations

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals To Present At 15th Annual BIO CEO & Investor Conference

RXi Pharmaceuticals To Present At 15th Annual BIO CEO & Investor Conference

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces Completion Of Enrollment In Second Phase 1 Trial For RXI-109 Program

RXi Pharmaceuticals Announces Completion Of Enrollment In Second Phase 1 Trial For RXI-109 Program

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals To Webcast Presentation At Biotech Showcase™ 2013

RXi Pharmaceuticals To Webcast Presentation At Biotech Showcase™ 2013

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals To Present At Biotech Showcase™ 2013

RXi Pharmaceuticals To Present At Biotech Showcase™ 2013

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Announces Initiation Of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109

RXi Pharmaceuticals Announces Initiation Of Second Double-Blind Vehicle Controlled Phase 1 Study With Its Anti-Scarring Compound, RXI-109

RXi Pharmaceuticals Corporation (OTC: RXII), today announced that dosing with their anti-scarring drug, RXI-109, for the management of surgical and hypertrophic scars and keloids has been initiated.

RXi Pharmaceuticals Announces Pharmacokinetic Results Of Its Single Dose Phase 1 Study With RXI-109 In Healthy Volunteers

RXi Pharmaceuticals Announces Pharmacokinetic Results Of Its Single Dose Phase 1 Study With RXI-109 In Healthy Volunteers

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Reports Financial Results For The Third Quarter Of 2012

RXi Pharmaceuticals Reports Financial Results For The Third Quarter Of 2012

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals To Present At 12th Annual Biotech Symposium

RXi Pharmaceuticals To Present At 12th Annual Biotech Symposium

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...

RXi Pharmaceuticals Awarded NCI SBIR Funding To Advance Self-Delivering RNAi Technology

RXi Pharmaceuticals Awarded NCI SBIR Funding To Advance Self-Delivering RNAi Technology

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...